BIOMAT Database Logo BIOMAT Database Logo

Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. 2010

V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Athens Eye Hospital, Second Eye Clinic, Athens, Greece.

Nearly every drug may cause changes to ocular tissues through a variety of mechanisms. Medication overdoses, drug-drug interactions but also chronic administration of medications at the recommended doses may lead to ocular toxicity. The ocular side effects, screening for eye toxicity and treatment guidelines for anti-inflammatory and immunosuppressive drugs commonly used by rheumatologists are reviewed herein.

UI MeSH Term Description Entries
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005128 Eye Diseases Diseases affecting the eye. Eye Disorders,Eye Disease,Eye Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite
D012216 Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. Rheumatism,Disease, Rheumatic,Diseases, Rheumatic,Rheumatic Disease
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine
D050071 Bone Density Conservation Agents Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. Antiresorptive Agent,Antiresorptive Agents,Antiresorptive Drugs,Bone Resorption Inhibitors,Bone Resorption Inhibitory Agents,Agent, Antiresorptive,Inhibitors, Bone Resorption,Resorption Inhibitors, Bone

Related Publications

V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
January 2019, Current rheumatology reviews,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Sarcopenia in rheumatic disorders: what the radiologist and rheumatologist should know.
March 2022, Skeletal radiology,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
What a rheumatologist should know about genetics.
December 1988, Bailliere's clinical rheumatology,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Nail psoriasis - what a rheumatologist should know about.
January 2017, Reumatologia,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
What rheumatologist should know about Fabry disease.
June 2020, Annals of the rheumatic diseases,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?
February 2024, Rheumatology (Oxford, England),
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Quality Measures 101: what every rheumatologist should know.
January 2007, Clinical and experimental rheumatology,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Pain medications. What you should know.
September 2007, Mayo Clinic health letter (English ed.),
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
[Side effects of tumor pharmacotherapy. What internists should know].
December 2011, Der Internist,
V Peponis, and V C Kyttaris, and S E Chalkiadakis, and S Bonovas, and N M Sitaras
Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition.
May 2013, Rheumatic diseases clinics of North America,
Copied contents to your clipboard!